Mei Pharma Stock Today
| MEIP Stock | USD 3.26 0.07 2.10% |
Performance0 of 100
| Odds Of DistressOver 70
|
MEI Pharma is selling at 3.26 as of the 24th of April 2024; that is -2.1 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.22. MEI Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for MEI Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of December 2003 | Category Healthcare | Classification Health Care |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.66 M outstanding shares of which 7.83 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover. More on MEI Pharma
Moving against MEI Stock
| 0.73 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.72 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.71 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.65 | ELYM | Eliem Therapeutics | PairCorr |
| 0.65 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.52 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.51 | ACB | Aurora Cannabis Trending | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
MEI Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. MEI Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding MEI Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO and President and Director | Daniel Gold | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering MEI Pharma report their recommendations after researching MEI Pharma's financial statements, talking to executives and customers, or listening in on MEI Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering MEI Pharma. The MEI consensus assessment is calculated by taking the average forecast from all of the analysts covering MEI Pharma. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from MEI Pharma's financial statements, MEI Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of MEI Pharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
MEI Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to MEI Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MEI Pharma's financial leverage. It provides some insight into what part of MEI Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
MEI Pharma (MEIP) is traded on NASDAQ Exchange in USA. It is located in 11455 El Camino Real, San Diego, CA, United States, 92130 and employs 46 people. MEI Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MEI Pharma's market, we take the total number of its shares issued and multiply it by MEI Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. MEI Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.66 M outstanding shares of which 7.83 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover.
MEI Pharma currently holds about 153.25 M in cash with (52.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15.
Check MEI Pharma Probability Of Bankruptcy
Ownership AllocationMEI Pharma holds a total of 6.66 Million outstanding shares. 30% of MEI Pharma outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thus, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check MEI Ownership Details
MEI Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of MEI Pharma jumping above the current price in 90 days from now is roughly 96.0%. The MEI Pharma probability density function shows the probability of MEI Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0444. This indicates MEI Pharma market returns are sensible to returns on the market. As the market goes up or down, MEI Pharma is expected to follow. Additionally, mEI Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of MEI Pharma to move above the current price in 90 days from now is roughly 96.0 (This MEI Pharma probability density function shows the probability of MEI Stock to fall within a particular range of prices over 90 days) .
MEI Stock Institutional Holders
Institutional Holdings refers to the ownership stake in MEI Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of MEI Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MEI Pharma's value.| Instituion | Recorded On | Shares | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 26.9 K | |
| Northern Trust Corp | 2023-12-31 | 24.8 K | |
| State Street Corporation | 2023-12-31 | 17.8 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 13.5 K | |
| Royal Bank Of Canada | 2023-12-31 | 11.9 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 10.9 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 5.9 K | |
| Group One Trading, Lp | 2023-12-31 | 5.7 K | |
| Newbridge Financial Services Group, Inc. | 2023-12-31 | 2 K | |
| Anson Funds Management Lp | 2023-12-31 | 1.1 M | |
| Cable Car Capital Llc | 2023-12-31 | 611.4 K |
MEI Pharma Historical Income Statement
MEI Pharma Income Statement is one of the three primary financial statements used for reporting MEI's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of MEI Pharma revenue and expense. MEI Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, MEI Pharma's Non Operating Income Net Other is relatively stable compared to the past year. As of 04/24/2024, Interest Income is likely to grow to about 4 M, though EBIT is likely to grow to (32.8 M). View More FundamentalsMEI Stock Against Markets
Picking the right benchmark for MEI Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in MEI Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for MEI Pharma is critical whether you are bullish or bearish towards MEI Pharma at a given time. Please also check how MEI Pharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in MEI Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
MEI Pharma Corporate Directors
MEI Pharma corporate directors refer to members of a MEI Pharma board of directors. The board of directors generally takes responsibility for the MEI Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of MEI Pharma's board members must vote for the resolution. The MEI Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Tamar Howson | Director | Profile | |
| Frederick Driscoll | Director | Profile | |
| Leah Cann | Independent Director | Profile | |
| Thomas Reynolds | Independent Director | Profile |
How to buy MEI Stock?
Before investing in MEI Pharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in MEI Pharma. To buy MEI Pharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of MEI Pharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase MEI Pharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located MEI Pharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased MEI Pharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as MEI Pharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy MEI Stock please use our How to Invest in MEI Pharma guide.
Already Invested in MEI Pharma?
The danger of trading MEI Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of MEI Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than MEI Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile MEI Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether MEI Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if MEI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Mei Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Mei Pharma Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for MEI Stock analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is MEI Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MEI Pharma. If investors know MEI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MEI Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.98 | Revenue Per Share 10.903 | Quarterly Revenue Growth 6.48 | Return On Assets 0.083 | Return On Equity 0.368 |
The market value of MEI Pharma is measured differently than its book value, which is the value of MEI that is recorded on the company's balance sheet. Investors also form their own opinion of MEI Pharma's value that differs from its market value or its book value, called intrinsic value, which is MEI Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MEI Pharma's market value can be influenced by many factors that don't directly affect MEI Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MEI Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if MEI Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MEI Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.